Clinical Trials and Corruption Risks

You may also like...

1 Response

  1. DJD says:

    Hi Michael,

    I’m curious as to why you say that the “Department of Justice and SEC have focused on the significant risk that companies may pay bribes to foreign physicians and healthcare officials to generate favorable clinical data.” I have not seen such a focus in the FCPA arena and would be very interested in any cases in which PI payments were alleged to be or found to be bribes under the FCPA.